Windlas Biotech Reports 25% YoY Growth in H1FY26 EBITDA, Achieves Highest Ever Half Yearly Revenue

Windlas Biotech Limited, a leading player in the domestic pharmaceutical formulations CDMO industry, reported its unaudited financials for the quarter ended September 30, 2025. The company achieved the highest ever half yearly revenue of Rs 432 crores, with a YoY growth of 19.4%. The EBITDA stood at Rs 55.1 crores, representing a 25.4% YoY growth, and EBITDA Margin came in at 12.7%. The PAT stood at Rs 35.5 crores, a growth of 21.7% YoY, with a PAT Margin of 8.2%. The company generated net operating cash flow of Rs 56 crores in H1FY26 and had a strong liquidity of Rs 237 crores as on 30th Sep 2025. The CDMO vertical contributed approximately 74% and 72% to the consolidated revenue for H1 & Q2 FY26 respectively, while the Trade Generics & Institutional vertical contributed approximately 22% and 23% for the same periods.